{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:27:09Z","timestamp":1788992829830,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68795-5","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:06:43Z","timestamp":1769414803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8473","authenticated-orcid":false,"given":"Jinshan","family":"Nan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-4113","authenticated-orcid":false,"given":"Huiping","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianzhao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaemin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lengjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-1252","authenticated-orcid":false,"given":"Yueshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronggang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-0554","authenticated-orcid":false,"given":"Jian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-9837","authenticated-orcid":false,"given":"Hin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-3746","authenticated-orcid":false,"given":"Shengyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"68795_CR1","unstructured":"W. H. O. World Health Organization (WHO). https:\/\/covid19.who.int (WHO, 2025)."},{"key":"68795_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"68795_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(22)00277-X","volume":"399","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. & Abu-Raddad, L. J. Waning effectiveness of COVID-19 vaccines.  Lancet 399, 771\u2013773 (2022).","journal-title":"Lancet"},{"key":"68795_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179 (2022).","journal-title":"Nat. Microbiol."},{"key":"68795_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"68795_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"68795_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"68795_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.abd7343","volume":"370","author":"CM Saad-Roy","year":"2020","unstructured":"Saad-Roy, C. M. et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science 370, 811\u2013818 (2020).","journal-title":"Science"},{"key":"68795_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.cell.2020.10.004","volume":"183","author":"AK Banerjee","year":"2020","unstructured":"Banerjee, A. K. et al. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 183, 1325\u20131339.e21 (2020).","journal-title":"Cell"},{"key":"68795_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41594-020-0511-8","volume":"27","author":"K Schubert","year":"2020","unstructured":"Schubert, K. et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat. Struct. Mol. Biol. 27, 959\u2013966 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"68795_CR11","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1128\/JVI.02220-08","volume":"83","author":"M Frieman","year":"2009","unstructured":"Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D. & Baric, R. S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-\u03baB signaling. J. Virol. 83, 6689\u20136705 (2009).","journal-title":"J. Virol."},{"key":"68795_CR12","doi-asserted-by":"publisher","first-page":"32208","DOI":"10.1074\/jbc.M704870200","volume":"282","author":"SG Devaraj","year":"2007","unstructured":"Devaraj, S. G. et al. Regulation of IRF-3-dependent Innate Immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282, 32208\u201332221 (2007).","journal-title":"J. Biol. Chem."},{"key":"68795_CR13","doi-asserted-by":"publisher","first-page":"34667","DOI":"10.1074\/jbc.M114.609644","volume":"289","author":"BA Bailey-Elkin","year":"2014","unstructured":"Bailey-Elkin, B. A. et al. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J. Biol. Chem. 289, 34667\u201334682 (2014).","journal-title":"J. Biol. Chem."},{"key":"68795_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662 (2020).","journal-title":"Nature"},{"key":"68795_CR15","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","volume":"78","author":"BH Harcourt","year":"2004","unstructured":"Harcourt, B. H. et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J. Virol. 78, 13600\u201313612 (2004).","journal-title":"J. Virol."},{"key":"68795_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273\u2013276 (2020).","journal-title":"Nature"},{"key":"68795_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"68795_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","volume":"31","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 31, 1212\u20131214 (2021).","journal-title":"Cell Res."},{"key":"68795_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","volume":"6","author":"J-L Zhang","year":"2021","unstructured":"Zhang, J.-L. et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Sig Transduct. Target Ther. 6, 414 (2021).","journal-title":"Sig Transduct. Target Ther."},{"key":"68795_CR20","doi-asserted-by":"crossref","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","DOI":"10.1126\/science.abl4784"},{"key":"68795_CR21","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"68795_CR22","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang, X. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 14, 6463 (2023).","journal-title":"Nat. Commun."},{"key":"68795_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat. Microbiol 9, 1075\u20131088 (2024).","journal-title":"Nat. Microbiol"},{"key":"68795_CR24","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia, K. et al. A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA 105, 16119\u201316124 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68795_CR25","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm401712t","volume":"57","author":"YM B\u00e1ez-Santos","year":"2014","unstructured":"B\u00e1ez-Santos, Y. M. et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J. Med. Chem. 57, 2393\u20132412 (2014).","journal-title":"J. Med. Chem."},{"key":"68795_CR26","doi-asserted-by":"publisher","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut, W. et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti\u2013COVID-19 drug design. Sci. Adv. 6, eabd4596 (2020).","journal-title":"Sci. Adv."},{"key":"68795_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/cmdc.202000548","volume":"16","author":"A Welker","year":"2021","unstructured":"Welker, A. et al. Structure-activity relationships of benzamides and isoindolines designed as SARS-CoV protease inhibitors effective against SARS-CoV-2. ChemMedChem 16, 340\u2013354 (2021).","journal-title":"ChemMedChem"},{"key":"68795_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.chembiol.2021.04.020","volume":"28","author":"H Shan","year":"2021","unstructured":"Shan, H. et al. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. Cell Chem. Biol. 28, 855\u2013865.e9 (2021).","journal-title":"Cell Chem. Biol."},{"key":"68795_CR29","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","volume":"7","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a flipGFP-based reporter assay. ACS Cent. Sci. 7, 1245\u20131260 (2021).","journal-title":"ACS Cent. Sci."},{"key":"68795_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell 12, 877\u2013888 (2021).","journal-title":"Protein Cell"},{"key":"68795_CR31","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","volume":"65","author":"Z Shen","year":"2022","unstructured":"Shen, Z. et al. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 65, 2940\u20132955 (2022).","journal-title":"J. Med. Chem."},{"key":"68795_CR32","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","volume":"65","author":"H Tan","year":"2022","unstructured":"Tan, H., Hu, Y., Jadhav, P., Tan, B. & Wang, J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. 65, 7561\u20137580 (2022).","journal-title":"J. Med. Chem."},{"key":"68795_CR33","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","volume":"14","author":"BC Sanders","year":"2023","unstructured":"Sanders, B. C. et al. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nat. Commun. 14, 1733 (2023).","journal-title":"Nat. Commun."},{"key":"68795_CR34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.adm9724","volume":"383","author":"B Tan","year":"2024","unstructured":"Tan, B. et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434\u20131440 (2024).","journal-title":"Science"},{"key":"68795_CR35","unstructured":"Garnsey, M. R. et al. Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model. Science AdvAnceS 10, 4288 (2024)."},{"key":"68795_CR36","doi-asserted-by":"publisher","first-page":"10169","DOI":"10.1038\/s41467-024-54462-0","volume":"15","author":"Y Lu","year":"2024","unstructured":"Lu, Y. et al. Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19. Nat. Commun. 15, 10169 (2024).","journal-title":"Nat. Commun."},{"key":"68795_CR37","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/s41467-025-57905-4","volume":"16","author":"S M. Bader","year":"2025","unstructured":"M. Bader, S. et al. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nat. Commun. 16, 2900 (2025).","journal-title":"Nat. Commun."},{"key":"68795_CR38","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41467-025-56902-x","volume":"16","author":"P Jadhav","year":"2025","unstructured":"Jadhav, P. et al. Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates. Nat. Commun. 16, 1604 (2025).","journal-title":"Nat. Commun."},{"key":"68795_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","volume":"12","author":"Z Fu","year":"2021","unstructured":"Fu, Z. et al. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat. Commun. 12, 488 (2021).","journal-title":"Nat. Commun."},{"key":"68795_CR40","doi-asserted-by":"publisher","first-page":"eade1985","DOI":"10.1126\/scisignal.ade1985","volume":"16","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression. Sci. Signal 16, eade1985 (2023).","journal-title":"Sci. Signal"},{"key":"68795_CR41","doi-asserted-by":"publisher","first-page":"eadd0082","DOI":"10.1126\/scisignal.add0082","volume":"16","author":"D Cao","year":"2023","unstructured":"Cao, D. et al. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING. Sci. Signal 16, eadd0082 (2023).","journal-title":"Sci. Signal"},{"key":"68795_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"68795_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"68795_CR44","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1038\/s41467-025-60832-z","volume":"16","author":"H Shuai","year":"2025","unstructured":"Shuai, H. et al. An orally available Mpro\/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. Nat. Commun. 16, 6541 (2025).","journal-title":"Nat. Commun."},{"key":"68795_CR45","doi-asserted-by":"publisher","first-page":"eadl4013","DOI":"10.1126\/sciadv.adl4013","volume":"10","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Sci. Adv. 10, eadl4013 (2024).","journal-title":"Sci. Adv."},{"key":"68795_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","volume":"589","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603\u2013607 (2021).","journal-title":"Nature"},{"key":"68795_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693\u2013699 (2022).","journal-title":"Nature"},{"key":"68795_CR48","doi-asserted-by":"publisher","first-page":"8728","DOI":"10.1038\/s41467-024-53033-7","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86\/JN.1 and EG.5.1\/HK.3. Nat. Commun. 15, 8728 (2024).","journal-title":"Nat. Commun."},{"key":"68795_CR49","doi-asserted-by":"publisher","unstructured":"Chu, H. et al. An orally available Mpro\/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. Res. Sq rs.3.rs-5454588 (2024) https:\/\/doi.org\/10.21203\/rs.3.rs-5454588\/v1.","DOI":"10.21203\/rs.3.rs-5454588\/v1"},{"key":"68795_CR50","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D. Biol. Crystallogr. 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"68795_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1107\/S0907444909042589","volume":"66","author":"A Vagin","year":"2010","unstructured":"Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D. Biol. Crystallogr. 66, 22\u201325 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"68795_CR52","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D. Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"68795_CR53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1107\/S2059798318000979","volume":"74","author":"O Kovalevskiy","year":"2018","unstructured":"Kovalevskiy, O., Nicholls, R. A., Long, F., Carlon, A. & Murshudov, G. N. Overview of refinement procedures within REFMAC 5: utilizing data from different sources. Acta Crystallogr D. Struct. Biol. 74, 215\u2013227 (2018).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"68795_CR54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"68795_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41586-022-05148-4","volume":"609","author":"H Chu","year":"2022","unstructured":"Chu, H. et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature 609, 785\u2013792 (2022).","journal-title":"Nature"},{"key":"68795_CR56","doi-asserted-by":"publisher","first-page":"103643","DOI":"10.1016\/j.ebiom.2021.103643","volume":"73","author":"H Shuai","year":"2021","unstructured":"Shuai, H. et al. Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine 73, 103643 (2021).","journal-title":"EBioMedicine"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68795-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68795-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68795-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:01:56Z","timestamp":1773108116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68795-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68795"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68795-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2035"}}